(Q47891308)

English

Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge

scientific article published on 26 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Plasmodium berghei

0 references

0 references

Escherichia coli

1 reference

based on heuristic

inferred from title

object named as

Elena Pettini

6

0 references

Donata Medaglini

object named as

Donata Medaglini

8

0 references

Giampietro Corradin

9

object named as

Giampietro Corradin

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

author name string

Jackeline F Romero

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Annalisa Ciabattini

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Philippe Guillaume

3

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Geraldine Frank

4

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Paolo Ruggiero

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Giuseppe Del Giudice

7

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

language of work or name

0 references

publication date

26 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

27

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

8

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

1266-1271

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

A review of human vaccine research and development: malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

NALT- versus Peyer's-patch-mediated mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Nasal tolerance induces antigen-specific CD4+CD25- regulatory T cells that can transfer their regulatory capacity to naive CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242–310 from the circumsporozoite protein of Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of ir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

The complexity of protective immunity against liver-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Cellular effector mechanisms against Plasmodium liver stages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Phosphonopeptides as Antibacterial Agents: Mechanism of Action of Alaphosphin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Isolation and characterization of mouse nasal-associated lymphoid tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Details of an isolation method for hepatic lymphocytes in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.010

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.12.010

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19111883

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47891308&oldid=2174866079"